Tridec-5-en-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Tridec-5-en-3-one
• 英文别名: (E)-tridec-5-en-3-one
• 化学式: C₁₃H₂₄O
• 分子量: 196.33
• InChiKey: VZVCJGQVOYLQCT-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Novel cyclopentenedione antifungal compounds and methods for their use
  申请人：Li Xing-Cong

  公开号：US20050215648A1

  公开（公告）日：2005-09-29

  Compounds and methods useful in the control, treatment, and prevention of fungal activity, of the following formula: where R 1-3 are independently H, alkyl, methyl, acyl, halogen, phenyl, R 4 is H, alkyl, methyl, acyl, alkoxy, halogen, phenyl provided that when R 3 is methyl and R 4 is H, R 1 and R 2 are not both H; and stereoisomers, analogs, and pharmaceutically acceptable salts thereof.

  在控制、治疗和预防真菌活性方面有用的化合物和方法，具有以下化学式：其中R1-3独立地是H、烷基、甲基、酰基、卤素、苯基，R4是H、烷基、甲基、酰基、烷氧基、卤素、苯基，但当R3是甲基且R4是H时，R1和R2不同时为H；以及其立体异构体、类似物和药用可接受的盐。
• Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
  申请人：——

  公开号：US20030229007A1

  公开（公告）日：2003-12-11

  The present invention provides a method for treating a human suffering from myocardial ischemia, cardiac arrhythmia, or both. The method comprises administering locally to a heart of a human an effective amount of an enzyme inhibitor that inhibits formation of angiotensin II in the heart. The invention also provides an isolated human renin of about 32-36 kDa.

  本发明提供了一种治疗心肌缺血、心律失常或两者兼有的人的方法。该方法包括向人的心脏局部施用有效量的酶抑制剂，该酶抑制剂可抑制血管紧张素 II 在心脏中的形成。本发明还提供了一种约 32-36 kDa 的分离人肾素。
• NOVEL CYCLOPENTENEDIONE ANTIFUNGAL COMPOUNDS AND METHODS FOR THEIR USE
  申请人：THE UNIVERSITY OF MISSISSIPPI

  公开号：EP1730095A2

  公开（公告）日：2006-12-13
• EP1730095A4
  申请人：——

  公开号：EP1730095A4

  公开（公告）日：2008-04-02
• Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
  申请人：Talley John Jeffrey

  公开号：US20090054319A1

  公开（公告）日：2009-02-26

  The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.